In a First, FDA Grants Full Approval to Anti-Amyloid Drug for Alzheimer's

On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive…

Read more...

administration agency alzheimer's alzheimers disease companies decision disease eli lilly fda food food and drug administration grants health medical pharma impact landscape major research